Article Text

PDF
Systemic antifungal prophylaxis for very low birthweight infants: a systematic review
  1. L Clerihew1,2,3,
  2. N Austin1,2,3,
  3. W McGuire1,2,3
  1. 1
    Ninewells Hospital and Medical School, Dundee, Scotland
  2. 2
    Christchurch Women’s Hospital, Christchurch, New Zealand
  3. 3
    Australian National University, Canberra, Australia
  1. W McGuire, Canberra Hospital, ACT 2606, Australia; william.mcguire{at}act.gov.au

Abstract

Systematic review and meta-analysis of four randomised controlled trials suggest that prophylactic fluconazole reduces the incidence of invasive fungal infection in very low birthweight infants. Further trials are needed to provide more precise estimates of effect size, and to assess the effect on mortality, neurodevelopment and the emergence of antifungal resistance.

Statistics from Altmetric.com

Footnotes

  • Competing interests: WMcG has received research funds from Pfizer UK Ltd, a manufacturer of fluconazole. This company had no role in the collection, analysis and interpretation of data, or in the writing of the report or decision to submit for publication.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.